, Volume 126, Issue 3, pp 206–218 | Cite as

Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory

  • J. Shepherd
  • D. J. Bill
  • C. T. Dourish
  • S. S. Grewal
  • A. McLenachan
  • K. J. Stanhope
Original Investigation


There is increasing interest in the potential functional role of the octapeptide angiotensin II (AII) in psychiatric and cognitive disorders. The novel angiotensin II (AII) receptor antagonists, losartan and PD123177, selective for the AT1 and AT2 receptor subtypes respectively, constitute important pharmacological tools for the assessment of the behavioural consequences of modulation of AII function. The present series of studies investigated the effects of each compound in two animal models of anxiety, the rat elevated zero-maze and mouse light/dark box, and two models of working memory in the rat, the operant delayed matching to position (DMTP) task and the spatial reinforced alternation test in the T-maze. Our data indicate that both compounds (0.01–10 mg/kg SC) were without significant effect in any of the behavioural assays. Using the present methods and strains of laboratory rodents, these findings provide no support for the involvement of AII receptor function in the mediation of anxiety or working memory.

Key words

Angiotensin II AT1 receptor AT2 receptor Losartan PD123177 Anxiety Working memory Elevated zero-maze Light/dark box Delayed matching to position test T-maze Cognition Rats Mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ (1990a) Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist. Neuroreport 1:20–21Google Scholar
  2. Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA, Naylor RJ (1990b) Cognitive enhancing actions of DuP753 detected in a mouse habituation paradigm. Neuroreport 1:239–242Google Scholar
  3. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ (1991) Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. Neuroreport 2:351–353Google Scholar
  4. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A (1994) The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur J Pharmacol 271:403–411Google Scholar
  5. Bill DJ, Fletcher A, Glenn BD, Knight M (1992) Behavioural studies on WAY-100289, a novel 5-HT3receptor antagonist, in two animal models of anxiety. Eur J Pharmacol 218:327–334Google Scholar
  6. Bill DJ, Brown G, McNicoll C, Fletcher A (1996) A comparison of the in vivo functional and anxiolytic potencies of a range of 5-HT1Areceptor ligands in the mouse. Neuropharmacology (in press)Google Scholar
  7. Blankley CJ, Hodges JC, Klutchko SR, Himmelsbach RJ, Chucholowski AW, Connolly CJ, Neergard SJ, Van-Nieuwenhze M, Sebastian A, Quin J, Essenburg AD, Cohen DM (1991) Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem 34:3248–3260Google Scholar
  8. Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor DG Jr, Timmermans PB (1991) Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 17:720–721Google Scholar
  9. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease L, Wong PC, Wexler RR, Johnson AL, Timmermans PB (1989) Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 165:196–203Google Scholar
  10. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PB (1990) Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252:711–718Google Scholar
  11. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1987) Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32:777–785Google Scholar
  12. Costall B, Coughlan J, Horovitz ZP, Kelly ME, Naylor R, Tomkins DM (1989). The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition. Pharmacol Biochem Behav 33:573–579Google Scholar
  13. Costall B, Domeney AM, Gerrard PA, Horovitz ZP, Kelly ME, Naylor RJ, Tomkins DM (1990) Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset. Pharmacol Biochem Behav 36:13–20Google Scholar
  14. Cox CP (1987) A handbook of introductory statistical methods. John Wiley, New YorkGoogle Scholar
  15. Crawley JN (1981) Neuropharmacologic specificity of a simple model for the behavioural actions of benzodiazepines. Pharmacol Biochem Behav 47:695–699Google Scholar
  16. Croog SH, Levine S, Testa MA, Bropwn B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH (1986) The effects of antihypertensive therapy on the quality of life. Engl J Med 314:1657–1664Google Scholar
  17. Deiken RF (1986) Captopril treatment in depression. Biol Psychiatry 21:1428–1452Google Scholar
  18. Dennes RP, Barnes JC (1993) Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and noncholinomimetic drugs using a novel task in the 12-arm radial maze. Psychopharmacology 111:435–441Google Scholar
  19. Dennes RP, Barnes JC, Michel AD, Tyers MB (1992) The effect of the AT1 receptor antagonist, losartan (DuP 753) on cognitive performance in the radial maze and in a delayed non-matching to position task in the rat. Br J Pharmacol 105:88PGoogle Scholar
  20. Dourish CT, Duggan JA, Banks RJA (1992) Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT1 receptor antagonist DuP 753 but not by the selective AT2 receptor antagonist WL 19. Eur J Pharmacol 211:113–116Google Scholar
  21. Dunnett SB (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87:357–363Google Scholar
  22. Gehlert DR, Gackenheimer SL, Reel JK, Lin H-S, Steinberg MI. (1990) Non-peptide angiotensin II receptor antagonists discriminate subtypes of125I-angiotensin II binding sites in the rat brain. Eur J Pharmacol 187:123–126Google Scholar
  23. Hendrie CA, Neill JC, Shepherd JK, Dourish CT (1993). The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 54:689–693Google Scholar
  24. Kaiser FC, Palmer GC, Wallace AV, Carr RD, Fraser-Rae L, Hallam C (1992) Antianxiety properties of the angiotensin II antagonist, DuP753, in the rat using the elevated plus-maze. Neuroreport 3:922–924Google Scholar
  25. Marshall FH, Clark SA, Michel AD, Barnes JC (1993) Binding of angiotensin II antagonists to rat liver and brain membranes measured ex-vivo. Br J Pharmacol 109:760–764Google Scholar
  26. Martin P (1994) Effects of losartan, an angiotensin II antagonist, alone and in combination with antidepressant drugs (ADS) in animal model of depression. FASEB J 8[4]:A378 (2187)Google Scholar
  27. Money EA, Kirk RC, McNaughton N (1992) Alzheimer's dementia produces a loss of discrimination but no increase in rate of memory decay in delayed matching to sample. Neuropsychologia 30:133–143Google Scholar
  28. Ravard S, Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271–273Google Scholar
  29. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and ParkinsonÕs disease. Brain 111:695–718Google Scholar
  30. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. (1994) Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety. Psychopharmacology 116:56–64Google Scholar
  31. Smith WT, Glaudin V, Cohen J, Sudilovsky A (1990) A pilot study of SQ29,852 in patients with generalised anxiety disorder. Proc 17th CINP, Kyoto, Japan, pp 12-1-12Google Scholar
  32. Stanhope KJ, Choules M, Yudko E, Dourish CT (1994). Reevaluation of the effects of putative cognitive disrupters in the reinforced-alternation T-maze task in the rat. Br J Pharmacol 112:15PGoogle Scholar
  33. Stanhope KJ, McLenachan AP, Dourish CT (1995) Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology 122:268–280Google Scholar
  34. Steckelings UM, Bottari SP, Unger T (1992) Angiotensin receptor subtypes in the brain. Trends Pharmacol Sci 13:365–368Google Scholar
  35. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JM, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205–251Google Scholar
  36. Wong PC, Price WA, Chiu, AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Non-peptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252:726–732Google Scholar
  37. Zubenko GA, Nixon RA (1984) Mood-elevating effects of captopril in depressed patients. Am J Psychiatry 141:110–111Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • J. Shepherd
    • 1
  • D. J. Bill
    • 1
  • C. T. Dourish
    • 1
  • S. S. Grewal
    • 1
  • A. McLenachan
    • 1
  • K. J. Stanhope
    • 1
  1. 1.Department of NeuropharmacologyWyeth Research (UK) Ltd., Huntercombe Lane South, TaplowMaidenheadUK

Personalised recommendations